Cardiomyocyte-specific overexpression of type 5 phosphodiesterase impairs postinfarction myocardial function and left ventricular remodeling
Péter Pokreisz(Ghent University), Stefan Janssens(Maastricht University), Hilde Gillijns(Ghent University), Ilse Lenaers, Luc Schoonjans(VIB-KU Leuven Center for Cancer Biology), Paul Herijgers(KU Leuven), Karin R. Sipido(KU Leuven), Glenn Marsboom(Johnson & Johnson (United States)), Pieter Vermeersch(Universitair Ziekenhuis Leuven), Virginie Bito(Hasselt University), Jan D’hooge(KU Leuven), Liesbeth Biesmans(Vlaams Instituut voor Biotechnologie), Marijke Pellens(Ghent University), Kenneth D. Bloch(Harvard University), An Van den Bergh(Vlaams Instituut voor Biotechnologie)
Circulation
October 1, 2007
Cited by 4
Related Papers
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
|Nature Medicine|2022|889
Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer
|The FASEB Journal|2012|606